Five analysts rate this biotech a STRONG BUY or a BUY as its products are used in such procedures as enhancing fusion in spine surgery; trading at around $2.00.

Rated a STRONG BUY by three analysts this provider of long term care to seniors has been showing steady revenue growth and good earnings; trading at around $3.50, near its yearly low.

* Subscribers may now login to view the current newsletter.

* Not a subscriber? SUBSCRIBE TODAY!

Five analysts rate this drug maker a STRONG BUY as it develops products for treating central nervous system disorders and pain; trading around $2.00.

Five analysts rate this media company a STRONG BUY or a BUY as it has carved a nice niche in air travel advertising; trading near its yearly low of $3.00.

* Subscribers may now login to view the current newsletter.

* Not a subscriber? SUBSCRIBE TODAY!

Rated a "STRONG BUY" or a 'BUY" by several analysts, this technology company has shown strong revenue growth for the last three years and posted a profit in 2011; trading at around $1.75.

Three analysts rate this provider to the semiconductor industry a "STRONG BUY" or a "BUY"; trading at under $3.00, it, too, has had good revenue growth for the last few years.

* Subscribers may now login to view the current newsletter.

* Not a subscriber? SUBSCRIBE TODAY!

OPNEXT. Closed position at $1.73 for a 19% LOSS.
(acquired by Oclaro)

* View the covered positions for the Newsletter Portfolio.
70% have been for GAINS of 50% or GREATER.

The Newsletter is published twice-monthly. Upon receipt of your subscription, we will e-mail a password, and further information, to you. Good Luck.

OREXIGEN THERAPEUTICS. Closed position at $5.12 for a 68% GAIN.

CERUS CORPORATION. Closed position at $4.50 for a 60% GAIN.

XATA CORP. Closed position at $1.33 for a 56% LOSS.

* View the covered positions for the Newsletter Portfolio.
70% have been for GAINS of 50% or GREATER.

The Newsletter is published twice-monthly. Upon receipt of your subscription, we will e-mail a password, and further information, to you. Good Luck.

Rated a STRONG BUY by three analysts, this developer of "needle free drug delivery" trades at around $2.00.

Also, rated a STRONG BUY by three analysts, this maker of hydrogen fuel cells trades at just under $2.00.

* Subscribers may now login to view the current newsletter.

* Not a subscriber? SUBSCRIBE TODAY!

VERMILLION, INC. Closed position at $2.95 for a 122% GAIN.

TRIDENT MICROSYSTEMS. Closed position at 35¢ for a 89% LOSS.

* View the covered positions for the Newsletter Portfolio.
70% have been for GAINS of 50% or GREATER.

The Newsletter is published twice-monthly. Upon receipt of your subscription, we will e-mail a password, and further information, to you. Good Luck.

GALENA BIOPHARMA. Closed position at $1.70 for a 70% GAIN.

KERYX BIOPHARMACEUTICALS. Closed position at $5.00 for a 67% GAIN.

MICROVISION. Closed position at $3.34 for a 88% LOSS.
(price reflects reverse split)

* View the covered positions for the Newsletter Portfolio.
70% have been for GAINS of 50% or GREATER.

The Newsletter is published twice-monthly. Upon receipt of your subscription, we will e-mail a password, and further information, to you. Good Luck.

Four analysts rate this cancer drug developer a STRONG BUY; owning a licensing deal with Duke University, the stock trades at a yearly low of nearly $2.00.

Rated a STRONG BUY or a MODERATE BUY by three analysts, this gaming company publishes video games for most of the majors; trading at around $2.50.

* Subscribers may now login to view the current newsletter.

* Not a subscriber? SUBSCRIBE TODAY!

CORCEPT THERAPEUTICS. Closed position at $4.86 for a 65% GAIN.

* View the covered positions for the Newsletter Portfolio.
70% have been for GAINS of 50% or GREATER.

The Newsletter is published twice-monthly. Upon receipt of your subscription, we will e-mail a password, and further information, to you. Good Luck.